Immunoengineering in glioblastoma imaging and therapy.
glioblastoma
imaging
immunoengineering
immunotherapy
nanomedicine
Journal
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
ISSN: 1939-0041
Titre abrégé: Wiley Interdiscip Rev Nanomed Nanobiotechnol
Pays: United States
ID NLM: 101508311
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
19
02
2019
revised:
18
06
2019
accepted:
19
06
2019
pubmed:
14
8
2019
medline:
21
8
2020
entrez:
14
8
2019
Statut:
ppublish
Résumé
Patients diagnosed with glioblastoma have poor prognosis. Conventional treatment strategies such as surgery, chemotherapy, and radiation therapy demonstrated limited clinical success and have considerable side effects on healthy tissues. A central challenge in treating brain tumors is the poor permeability of the blood-brain barrier (BBB) to therapeutics. Recently, various methods based on immunotherapy and nanotechnology have demonstrated potential in addressing these obstacles by enabling precise targeting of brain tumors to minimize adverse effects, while increasing targeted drug delivery across the BBB. In addition to treating the tumors, these approaches may be used in conjunction with imaging modalities, such as magnetic resonance imaging and positron emission tomography to enhance the prognosis procedures. This review aims to provide mechanistic understanding of immune system regulation in the central nervous system and the benefits of nanoparticles in the prognosis of brain tumors. This article is characterized under: Diagnostic Tools > in vivo Nanodiagnostics and Imaging Nanotechnology Approaches to Biology > Cells at the Nanoscale Nanotechnology Approaches to Biology > Nanoscale Systems in Biology.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1575Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2019 Wiley Periodicals, Inc.